1Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long - term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology ,2006,131 ( 6 ) : 1743.
2Park NH, Chung YH. Molecular mechanisms of hepatitis B virus asso-ciated hepatocellular carcinoma[ J]. Korean J Hepatol,2007,13 ( 3 ) : 320.
3Yu M W, Yeh S H, Chen P J, et al. Hepatitis B virus genotype and DNA level and hepatocellular earcinoma:a prospective study in men[J]. J Natl Cancer Inst,2005,97 (4) :265.
4Chen C J, Yang H J, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepaitis B virus DNA level[J]. JMAM ,2006,295( 1 ) :65.
5Zhou JY, Zhang L, Li L. High Hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients : a case conttrol study[J]. Virology Journal ,2012,9 ( 1 ) : 16.
6Kubo S, Tanaka H, Tanaka H, et al. Effect of viral status on recur- rence after liver resection for patients with hepatitis B virus related hepatocelluar carcinoma[J]. Cancer,2000,88 ( 5 ) : 1016.
7Chin R, Earnest - Silveira L, Koeberlein B, et al. Modulation of M- APK pathways and cell cycle by replicating hepatitis B virus:factors contributing to hepatocarcino genesis[J]. J Hepatol, 2007,47 ( 3 ) : 325.
8Feitelson MA. Parallel epigenetic and genetic change in the pathogen- esis of hepatitis virus associated hepatocellular carcinoma[J]. Cancer Lett ,2006,239 ( 1 ) : 10.
2wBonilla Guerrero R, Roberts L R. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellu- lar carcinoma[ J ]. J Hepatol, 2005,42:760-777.
3Murakami Y, Minami M, Daimon Y, et al. Hepatitis B vi- rus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen[J]. J Med Virol, 2004,72:203-214.
4Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatoeellular carcinomas[ J]. Gut, 2005,54 : 1162- 1168.
5Buckwold V E, Xu Z, Chen M, et al. Effects of a naturally occuring mutation in the hepatitis B virus basal core promot-er on precore gene expression and viral replication [ J ]. J Virol, 1996,70 : 5845- 5851.
6Chou Y C, Yu M W, Wu C F, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma [ J]. Gut, 2008,57:91--97.
7Yuen M F, Tanaka Y, Shinkai N, et al. Risk for hepato- cellular carcinoma with respect to hepatitis B virus geno- types B/C, specific mutations of enhancer II./core promot- er/precore regions and HBV DNA levels [ J ]. Gut, 2008, 57:98-102.
8Minami M, Poussin K, Br6chot C, et al. A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome[ J]. Genomics, 1995,29:403-408.
9Wang Y, Lau S H, Sham J S, et al. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of tluncated X gene and hepatocellular carcinogenesis [ J ]. Oncogene, 2004,23 : 142-148.
10Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomer- ase gene[ J ]. Oncogene, 2003,22:3911- 3916.
